| A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma (NCT00457782) | Kyowa Kirin Co., Ltd. | 2007-04-01 |
| Quality of Life in Multiple Myeloma Patients Treated With Bortezomib (NCT01021592) | Janssen Korea, Ltd., Korea | 2007-03-01 |
| A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma (NCT00431340) | Valerio Therapeutics | 2007-03-01 |
| Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma (NCT00461045) | Celgene | 2007-03-01 |
| Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies (NCT00446342) | Sunesis Pharmaceuticals | 2007-02-01 |
| The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer) (NCT00436059) | Vejle Hospital | 2007-02-01 |
| RMPT for Relapsed/Refractory Multiple Myeloma (NCT00961467) | Fondazione EMN Italy Onlus | 2007-02-01 |
| Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma (NCT00784823) | Hackensack Meridian Health | 2007-01-01 |
| Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma (NCT00652041) | PETHEMA Foundation | 2007-01-01 |
| Phase I/II Study of hLL1 in Multiple Myeloma (NCT00421525) | Gilead Sciences | 2007-01-01 |
| A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b (NCT00423644) | Alaunos Therapeutics | 2007-01-01 |
| Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma (NCT00415064) | AEterna Zentaris | 2006-12-01 |
| A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma (NCT01801436) | Johnson & Johnson Taiwan Ltd | 2006-12-01 |
| Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma (NCT00425347) | Facet Biotech | 2006-12-01 |
| Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma (NCT00412919) | Bayside Health | 2006-12-01 |
| A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma (NCT00434161) | Swedish Orphan Biovitrum | 2006-12-01 |
| Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma (NCT00441168) | Janssen-Cilag International NV | 2006-12-01 |
| A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma (NCT00416273) | Janssen-Cilag G.m.b.H | 2006-12-01 |
| Collection of Patient-Reported Symptoms and Performance Status Via the Internet (NCT00417040) | Alliance for Clinical Trials in Oncology | 2006-12-01 |
| Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma (NCT00972712) | Emory University | 2006-12-01 |
| A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma (NCT00401843) | Janssen Research & Development, LLC | 2006-11-28 |
| Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year (NCT00424983) | Novartis Pharmaceuticals | 2006-11-01 |
| UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy (NCT00572169) | University of Arkansas | 2006-11-01 |
| A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma (NCT00420849) | Celgene Corporation | 2006-11-01 |
| A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma (NCT00431990) | Peter MacCallum Cancer Centre, Australia | 2006-11-01 |
| Combined Haploidentical-Cord Blood Transplantation for Adults and Children (NCT00943800) | University of Chicago | 2006-10-09 |
| Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells (NCT00398411) | University of Cologne | 2006-10-01 |
| HD Melphalan and SCT in Patients With IGDD or LCDD (NCT00681044) | Boston Medical Center | 2006-10-01 |
| Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma (NCT00416208) | Janssen-Cilag G.m.b.H | 2006-10-01 |
| Cellular Therapy With Cord Blood Cells (NCT00427557) | M.D. Anderson Cancer Center | 2006-10-01 |
| An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma (NCT00402181) | Centocor, Inc. | 2006-10-01 |
| A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma (NCT00915408) | King's College Hospital NHS Trust | 2006-09-01 |
| Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma (NCT01233895) | Sanofi | 2006-09-01 |
| ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. (NCT00440479) | Janssen-Cilag B.V. | 2006-09-01 |
| Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma (NCT00378105) | Dana-Farber Cancer Institute | 2006-09-01 |
| Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant (NCT00388999) | Enzon Pharmaceuticals, Inc. | 2006-09-01 |
| Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma (NCT00378209) | Dana-Farber Cancer Institute | 2006-08-01 |
| High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma (NCT00349778) | Stanford University | 2006-08-01 |
| EMMA-1 (Erbitux for Multiple Myeloma) (NCT00368121) | Prof. Dr. Andreas Engert | 2006-08-01 |
| Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2 (NCT00573391) | University of Arkansas | 2006-08-01 |
| Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients (NCT00401011) | AEterna Zentaris | 2006-08-01 |
| Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) (NCT00871663) | Merck Sharp & Dohme LLC | 2006-08-01 |
| Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies (NCT00460694) | Singapore General Hospital | 2006-08-01 |
| Collection of Tissue Samples for Cancer Research (NCT00900198) | National Cancer Institute (NCI) | 2006-07-06 |
| UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies (NCT00578045) | University of Arkansas | 2006-07-01 |
| UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide (NCT00574080) | University of Arkansas | 2006-07-01 |
| Etiology of Multiple Myeloma: A Case-Control Study (NCT00505999) | M.D. Anderson Cancer Center | 2006-07-01 |
| Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma (NCT00366106) | Accelerated Community Oncology Research Network | 2006-07-01 |
| Two Cycles of PAD Combination by AHCT in MM (NCT01370434) | Cooperative Study Group A for Hematology | 2006-07-01 |
| An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma (NCT00431769) | Janssen-Cilag International NV | 2006-06-01 |
| A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma (NCT00352742) | Attenuon | 2006-06-01 |
| Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse (NCT00335348) | Peter MacCallum Cancer Centre, Australia | 2006-06-01 |
| Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS) (NCT01005628) | Janssen Korea, Ltd., Korea | 2006-06-01 |
| Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662). (NCT00741780) | Genzyme, a Sanofi Company | 2006-06-01 |
| TCD Followed by autoSCT for Newly Diagnosed MM Patients (NCT00349115) | Korean Multiple Myeloma Working Party | 2006-06-01 |
| Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients (NCT01063179) | Fondazione EMN Italy Onlus | 2006-05-01 |
| A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma (NCT02079519) | Hoffmann-La Roche | 2006-05-01 |
| Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma (NCT00315757) | Human Genome Sciences Inc. | 2006-05-01 |
| Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies (NCT00477035) | Sally Arai | 2006-05-01 |
| Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) (NCT00689000) | Chroma Therapeutics | 2006-05-01 |
| VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM) (NCT01134484) | Michele Cavo | 2006-05-01 |
| PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation (NCT00352703) | Swedish Orphan Biovitrum | 2006-04-01 |
| VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates (NCT00320476) | Korean Multiple Myeloma Working Party | 2006-04-01 |
| An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade (NCT01675245) | Xian-Janssen Pharmaceutical Ltd. | 2006-03-01 |
| GEM05 for Patients With Multiple Myeloma Under 65 Years (NCT00461747) | PETHEMA Foundation | 2006-03-01 |
| Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation. (NCT00306735) | Eisai Inc. | 2006-03-01 |
| Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma (NCT00934154) | Cigdem Sahinbas YILMAZ | 2006-03-01 |
| A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy (NCT00833560) | Janssen-Cilag G.m.b.H | 2006-03-01 |
| Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM (NCT00378755) | Korean Multiple Myeloma Working Party | 2006-03-01 |
| Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma (NCT00291538) | Nantes University Hospital | 2006-02-01 |
| The Effect of High Dose Simvastatine on Multiple Myeloma (NCT00281476) | Vejle Hospital | 2006-02-01 |
| Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients (NCT00406978) | Silvio Aime | 2006-02-01 |
| Bortezomib-Dexamethasone-Doxorubicin-Study (NCT00401804) | Austrian Forum Against Cancer | 2006-02-01 |
| Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma (NCT02739594) | Hoffmann-La Roche | 2006-02-01 |
| Study of XL999 in Patients With Multiple Myeloma (NCT00304590) | Symphony Evolution, Inc. | 2006-02-01 |
| Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma (NCT00452569) | Celgene | 2006-02-01 |
| Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation (NCT00698685) | University of Arizona | 2006-01-23 |
| Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001) (NCT00701103) | Merck Sharp & Dohme LLC | 2006-01-12 |
| Study of Immune Response Modifier in the Treatment of Hematologic Malignancies (NCT00276159) | Masonic Cancer Center, University of Minnesota | 2006-01-01 |
| Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma (NCT01622582) | University of Arkansas | 2006-01-01 |
| Trial of AVN-944 in Patients With Advanced Hematologic Malignancies (NCT00273936) | Vertex Pharmaceuticals Incorporated | 2006-01-01 |
| Quality of Life in Patients With Multiple Myeloma (NCT00290095) | Ullevaal University Hospital | 2006-01-01 |
| Study of ZIO-101 in Multiple Myeloma (NCT00303199) | Alaunos Therapeutics | 2006-01-01 |
| Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients (NCT00417911) | Nordic Myeloma Study Group | 2005-12-01 |
| Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma (NCT00375791) | AEterna Zentaris | 2005-12-01 |
| A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients (NCT00561743) | Janssen-Ortho Inc., Canada | 2005-11-01 |
| PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma (NCT00319865) | Korean Multiple Myeloma Working Party | 2005-11-01 |
| Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients (NCT00327249) | AmpliMed Corporation | 2005-10-01 |
| VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) (NCT00311337) | University of Wuerzburg | 2005-10-01 |
| A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone (NCT00234169) | Peter MacCallum Cancer Centre, Australia | 2005-10-01 |
| Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma (NCT00179647) | Celgene Corporation | 2005-09-01 |
| Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (NCT00598624) | IRCCS San Raffaele | 2005-09-01 |
| Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen (NCT00804947) | Fundacion Para La Investigacion Hospital La Fe | 2005-09-01 |
| PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma (NCT00240162) | Washington University School of Medicine | 2005-09-01 |
| Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies (NCT00150462) | Amgen | 2005-09-01 |
| Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) (NCT00111813) | Merck Sharp & Dohme LLC | 2005-09-01 |
| Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma (NCT00231166) | Novartis Pharmaceuticals | 2005-09-01 |
| CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation (NCT00333190) | Dana-Farber Cancer Institute | 2005-09-01 |
| Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma (NCT00135200) | University of Michigan Rogel Cancer Center | 2005-08-01 |
| VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma (NCT00391157) | PETHEMA Foundation | 2005-08-01 |